Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Reports Second Quarter 2018 Financial Results

Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue TEGSEDI approved and on track to launch in the EU Positive FDA Advisory Committee vote recommending approval of WAYLIVRA Conference call and webcast today, August 7, 2018, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Aug.